Toxic epidermal necrolysis

Lancet

Volumn 351, Issue 9113, 1998, Pages 1417-1420

  Becker, David S ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN;

CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; TOXIC EPIDERMAL NECROLYSIS;

EID: 0032499461     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11369-1     Document Type: Review

References (32)

1. 1 Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68; 355-61.
2. 2 Elias P, Fritsch P, Epstein E. Staphylococcal scalded skin syndrome: clinical features, pathogenesis and recent microbiological and biochemical developments. Arch Dermatol 1977; 113: 207-19.
3. 3 Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922; 24: 526-33.
4. 4 Roujeua J, Chosidow O, Saiag P, Guillaume J. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 6: 1039-53.
5. 5 Roujeau J. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a c.linical classificstion. J Invest Dermatol 1994; 102: 28S-30S.
6. 6 Bastuji-Garin S, Rzany B, Stern R, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1966; 129: 92-96.
7. 7 Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13: 623-35.
8. 8 Goldstein S, Wintroub B, Elias P, Wuepper K. Toxic epidermal necrolysis: unmuddying the waters. Arch Dermatol 1987; 123: 1153-56.
9. 9 Rzany B, Mockenhaupt M, Baur S, et al. Epidermiology of erythema excudativum multiform majus, Stevens-Johnson Syndrome, and toxic epidermal necrolysis in Germany (1990-1992); structure and results of a population-based registry. J Clin Epidermiol 1996; 49: 769-73.
10. 10 Saiag P, Caumes E, Chopsidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1990; 26: 567-74.
11. 11 Villada G, Roujeau J, Cordonnier C, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23: 870-75.
12. 12 Rasmussen J. Toxic epidermal necrolysis. Med Clin North Am 1980: 64: 901-20.
13. 13 Goodman H. Nikolsky sign. Arch Dermatol Syphilol 1953; 68: 334.
14. 14 Revuz J, Penso D, Roujeau J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-65.
15. 15 Power W, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the cute ophthalmic manifestations of erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669-76.
16. 16 McIvor R, Zaidi J, Peters W, Hyland R. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17: 237-40.
17. 17 Krumlovsky F, Del Greco F, Herdson P, Lazar P. Renal disease associated with toxic epidermal necrolysis (Lyell's disease). 1975; 57: 817-25.
18. 18 Avakian R, Flowers F, Araujo O, Ramos-Caro F. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69-79.
19. 19 Guillaume J, Roujeau J, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 1987; 123: 1166-70.
20. 20 Roujeau J, Kelly J, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 24: 1600-07.
21. 21 Ackerman A, Niven J, Grant-Kels J. Differential diagnosis in dermatopathology. Philadelphia: Lea & Febiger, 1982: 26-29.
22. 22 Villada G, Roujeau J, Clérici T, Bourgault I, Revuz J. Immunopathology of toxic epidermal necrolysis: keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1922; 128: 50-53.
23. 23 Miyauchi H, Hosokawa H, Akaeda T, Hitoki I, Asada Y. T-cell subsets in drug-induced toxic epidermal necrolysis. Arch Dermatol 1991; 127: 851-55.
24. 24 Correia O, Delgado L, Ramos J, Resende C, Torrinha J. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Arch Dermatol 1993; 129: 466-68.
25. 25 Shear N, Spielberg S, Grant D, Tang B, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
26. 26 Wolkestein P, Charue D, Laurent P, Revuz J, Roujeau J, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1955; 131: 544-51.
27. 27 Heimbach D, Engrav L, Marvin J, Harnar T, Grube B. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171-75.
28. 28 Halebian P, Madden M, Finglestein J, Corder V, Shires G. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12.
29. 29 Fine J. Management of acquired bullous skin diseases. N Engl J Med 1995; 133: 1475-84.
30. 30 Stables G, Lever R. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993; 128: 357-60.
31. 31 Rzany B, Schmitt H, Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71: 171-72.
32. 33 Renfro L, Grant-Kels J, Daman L. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989; 28: 441-44.